Company Directory

Clinical-stage antifungal drug developer targeting invasive fungal infections

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals. Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.

High-sensitivity lateral flow diagnostics for point-of-care testing

SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies. Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist equipment or laboratory facilities. The company's first commercial product is a rapid mycoplasma contamination detection kit for cell culture applications. Further products in development target HIV, dengue fever, hepatitis C, and prostate cancer.

Polymer-embedded antimicrobial technology for infection prevention in medical devices

Zonova is a biotech company developing patented antimicrobial technology embedded into medical device polymers at the manufacturing stage. The technology creates a protective surface that continuously kills a broad spectrum of pathogens, including drug-resistant strains such as MRSA. Applications span catheters, cannulas, endotracheal tubes, and surgical sutures. Zonova's commercial model is B2B licensing to medical device manufacturers, within a One Health approach to tackling antimicrobial resistance.

Multiplex qPCR and NGS kits for molecular detection

YouSeq is a UK manufacturer of multiplex Next Generation Sequencing and qPCR kits, panels and reagents. The company offers one of the largest menus of qPCR targets available, covering human infectious diseases, antimicrobial resistance profiling, food and water safety, microbiome analysis, and veterinary diagnostics. Products are supplied as complete, ready-to-use kits compatible with standard laboratory platforms, serving clinical, research, and diagnostic laboratory customers.

Enzymatic wound debridement therapy derived from maggot biology

SolasCure is a biotechnology company developing a recombinant enzyme-based hydrogel for the treatment of chronic wounds. The lead product contains a protease cloned from medical maggots that degrades non-viable wound tissue including fibrin, elastin, and collagen to prepare the wound bed for healing. The product is in Phase II clinical development for venous leg ulcers, with anti-biofilm activity as a secondary indication under investigation.

AI-powered microbiome and phage therapy platform for gut disorders

GutSee Health is a biotechnology company developing precision microbiome therapies for gut disorders including irritable bowel syndrome and inflammatory bowel disease. Its AI discovery platform integrates multi-omics and microbiome data to identify molecular disease signatures and therapeutic targets. A parallel programme uses machine learning to design targeted bacteriophage interventions that selectively remove harmful gut microbes and address antimicrobial-resistant wound infections.

Infectious disease drug development and partnering organisation

Infex Therapeutics is a clinical-stage drug development company focused on antimicrobial resistance and pandemic-priority infectious diseases, based at Alderley Park. Founded as The AMR Centre in 2016, the company acquires and co-develops novel therapeutics through in-licensing and risk-sharing partnerships with biotechs, universities and pharmaceutical companies, supporting programmes from lead optimisation to Phase 2 proof of concept. Its pipeline includes programmes targeting drug-resistant Gram-negative bacteria, respiratory infections and urinary tract infections.

Non-invasive deep lung breath sampling device for molecular research

PulmoBioMed is a medical technology company developing a handheld device for collecting exhaled breath condensate from the lower respiratory tract without contamination from the upper airway or oral cavity. The device provides uncontaminated lung-derived samples for downstream molecular analysis including proteomics, metabolomics, microbiology, and nucleic acid profiling. Applications span respiratory disease diagnosis, pulmonary biomarker discovery, antimicrobial resistance research, pharmacokinetics, and toxicology screening. A clinical configuration targets point-of-need asthma diagnosis.

Digital microscope platform for veterinary parasite diagnostics

Techion (UK) is the UK subsidiary of New Zealand-founded Techion Group, developer of an integrated digital diagnostics platform for parasite management in production animals. Its FECPAKG2 system combines a portable digital microscope with cloud-based image analysis and decision support software, enabling on-farm faecal egg count testing without specialist laboratory infrastructure. The platform supports evidence-based anthelmintic prescribing to address wormer resistance, with expanding applications in human and environmental diagnostics.

Portable multiplex PCR molecular diagnostic platform for point-of-care use

QuantuMDx is a medical technology company developing a battery-operated, handheld molecular diagnostic system that delivers multiplex PCR results from a single-use reagent cassette within 35 minutes. Designed for point-of-care and resource-limited settings, the CE-IVD marked device supports assays for respiratory infections, tuberculosis, sexually transmitted infections, and HPV. The company's technology provides complementary pathogen concentration and nucleic acid extraction capabilities.

Global drug discovery and development partnership company

Evotec is a global drug discovery and development company with major UK operations at Milton Park, Abingdon, and Alderley Park, Cheshire. Its Abingdon campus houses over 800 staff spanning target validation, medicinal chemistry, structural biology, in silico design, process development, and biologics manufacturing capabilities. The Alderley Park site focuses on antimicrobial and infectious disease research alongside preclinical ADME-tox services through subsidiary Cyprotex. Evotec partners with pharma and biotech companies across multiple therapeutic areas.

Controlled-release orthobiologics for spinal fusion and bone repair

Locate Bio is a clinical-stage biotechnology company developing a portfolio of orthobiologic products for musculoskeletal surgery. Its proprietary Programmed Drug Release platform encapsulates recombinant proteins within biodegradable polymer scaffolds to enable controlled, extended-release delivery. Lead product LDGraft is an rhBMP-2 bone graft substitute in clinical trial for lumbar interbody fusion, having received FDA Breakthrough Device Designation. The pipeline also includes synthetic bone graft substitutes and antibiotic-eluting scaffolds for osteomyelitis.